{"id":17843,"date":"2026-02-04T13:07:00","date_gmt":"2026-02-04T13:07:00","guid":{"rendered":"https:\/\/readtrends.com\/en\/lilly-q4-glp1-sales-soar\/"},"modified":"2026-02-04T13:07:00","modified_gmt":"2026-02-04T13:07:00","slug":"lilly-q4-glp1-sales-soar","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/lilly-q4-glp1-sales-soar\/","title":{"rendered":"Lilly Crushes Q4 Estimates, Forecasts $80\u201383B as GLP\u20111 Sales Surge"},"content":{"rendered":"<article>\n<p><strong>Lead:<\/strong> Eli Lilly reported a stronger-than-expected fourth quarter on Feb. 4, 2026, driven by surging demand for its GLP\u20111 drugs Zepbound and Mounjaro. The company posted $19.29 billion in Q4 revenue and a sharply raised 2026 revenue outlook of $80 billion to $83 billion, well above analysts&#8217; $77.62 billion projection. Lilly also set adjusted EPS guidance of $33.50\u2013$35.00 for 2026, exceeding the LSEG consensus of $33.23. Shares jumped in premarket trading as the results underscored rapidly growing volumes despite downward pressure on realized prices.<\/p>\n<h2>Key takeaways<\/h2>\n<ul>\n<li>Lilly reported Q4 revenue of $19.29 billion, up 43% year\u2011over\u2011year, beating the LSEG consensus of $17.96 billion.<\/li>\n<li>Adjusted Q4 EPS was $7.54 versus expectations of $6.67; GAAP net income for the quarter was $6.64 billion ($7.39\/sh).<\/li>\n<li>Mounjaro generated $7.41 billion in Q4 revenue (up 110% YoY); U.S. Mounjaro sales were $4.1 billion, up 57%.<\/li>\n<li>Zepbound posted $4.2 billion in U.S. Q4 revenue, a 122% increase YoY and above StreetAccount&#8217;s $3.91 billion estimate.<\/li>\n<li>For 2026 Lilly guided revenue of $80\u2013$83 billion (midpoint implies ~25% growth) and adjusted EPS of $33.50\u2013$35.00.<\/li>\n<li>The company expects a low\u2011 to mid\u2011teens percentage global pricing decline tied to the Trump administration deal, new direct\u2011to\u2011consumer rates and lower Medicaid pricing on some legacy products.<\/li>\n<li>Lilly cited Medicare coverage expansion and a pending GLP\u20111 oral obesity pill expected in Q2 (pending U.S. approval) as growth drivers.<\/li>\n<li>Lilly&#8217;s U.S. market share for obesity and diabetes drugs rose to 60.5% in Q4 versus 39.1% for Novo Nordisk.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>Global demand for GLP\u20111 therapies accelerated dramatically in 2023\u20132025, reshaping the obesity and diabetes drug market and producing multi\u2011billion dollar blockbusters. Lilly and Novo Nordisk emerged as the dominant suppliers, each developing injectable and oral formulations that widened patient access. In late 2025 both companies struck agreements with the U.S. administration to lower prices for Medicare and Medicaid beneficiaries and to offer discounted direct\u2011to\u2011consumer options via a White House platform, a policy shift intended to broaden access while lowering government drug costs.<\/p>\n<p>Those pricing deals create a trade\u2011off: broader patient coverage and higher prescription volumes in return for lower realized prices per unit. Policymakers and payers have signaled further attention to affordability, while manufacturers are adapting commercial strategies to preserve margins through volume growth, new formulations and international pricing. Competition has also intensified with planned launches of oral GLP\u20111s and new brands entering major markets including the U.S., China, Brazil and Canada where exclusivity dynamics are changing.<\/p>\n<h2>Main event<\/h2>\n<p>On Feb. 4, 2026 Lilly released fourth\u2011quarter results showing revenue of $19.29 billion and adjusted EPS of $7.54, both materially above Wall Street expectations. The company attributed the upside to a roughly 50% increase in global volume for its key products, led by Mounjaro and Zepbound, while acknowledging that realized prices for those drugs declined. Net income on a GAAP basis rose to $6.64 billion from $4.41 billion a year earlier.<\/p>\n<p>Mounjaro posted $7.41 billion in revenue for the quarter, a 110% year\u2011over\u2011year gain; U.S. sales alone were $4.1 billion, up 57%. Zepbound delivered $4.2 billion in U.S. revenue, a 122% increase from the prior year and above StreetAccount estimates. Management said prescription volume gains, not price increases, were the primary driver of the revenue jump.<\/p>\n<p>Lilly provided 2026 guidance calling for $80\u2013$83 billion in revenue and $33.50\u2013$35.00 in adjusted EPS. Management flagged several tailwinds: expanded Medicare coverage for obesity treatments, continued strong global demand for Mounjaro and Zepbound, and an anticipated U.S. launch of an oral GLP\u20111 pill for obesity in Q2, subject to regulatory approval. At the same time the company warned of a low\u2011 to mid\u2011teens percentage global pricing decline tied to the Trump administration agreement, new direct\u2011to\u2011consumer pricing, and lower Medicaid rates for some older products.<\/p>\n<h2>Analysis &#038; implications<\/h2>\n<p>Lilly\u2019s results illustrate how volume growth can offset\u2014and in some cases outpace\u2014downward pressure on prices. A midpoint revenue forecast of $81.5 billion implies roughly 25% year\u2011over\u2011year growth, signaling that prescription uptake and new patient access may more than compensate for per\u2011unit price cuts in 2026. That dynamic is central to Lilly\u2019s strategy: broaden the pool of treated patients through coverage expansions and new product forms.<\/p>\n<p>The company\u2019s ability to expand market share to 60.5% in the U.S. for obesity and diabetes drugs suggests operational advantages in distribution, prescriber relationships and inventory management. Yet falling realized prices will compress gross margins on GLP\u20111s unless offset by cost efficiencies, higher treatment adherence, or premium products. Investors will watch how quickly volume gains translate into steady cash flow at the lower price points.<\/p>\n<p>Competitively, the divergence between Lilly and Novo Nordisk\u2019s near\u2011term outlooks is notable. Novo warned of an as\u2011much\u2011as 13% decline in sales and profit in 2026, citing price reductions and loss of exclusivity in several international markets. Lilly\u2019s bullish guidance indicates management expects stronger net benefits from U.S. coverage expansions and upcoming product launches, though outcomes hinge on regulatory timing, payer implementation and direct\u2011to\u2011consumer platform execution.<\/p>\n<h2>Comparison &#038; data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Item<\/th>\n<th>Q4 2025<\/th>\n<th>YoY change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Total revenue<\/td>\n<td>$19.29B<\/td>\n<td>+43%<\/td>\n<\/tr>\n<tr>\n<td>Mounjaro (total)<\/td>\n<td>$7.41B<\/td>\n<td>+110%<\/td>\n<\/tr>\n<tr>\n<td>Mounjaro (U.S.)<\/td>\n<td>$4.10B<\/td>\n<td>+57%<\/td>\n<\/tr>\n<tr>\n<td>Zepbound (U.S.)<\/td>\n<td>$4.20B<\/td>\n<td>+122%<\/td>\n<\/tr>\n<tr>\n<td>U.S. obesity\/diabetes market share (Lilly)<\/td>\n<td>60.5%<\/td>\n<td>+2.6 ppt vs Q3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>The table summarizes headline Q4 figures cited by Lilly and independent data providers. Volume increases\u2014about a 50% rise in units sold in the U.S.\u2014were the principal driver of U.S. revenue growth ($12.9 billion). Management notes that realized prices fell, with a planned global pricing decline in the low\u2011 to mid\u2011teens percent range, a factor investors must weigh when modeling 2026 margins.<\/p>\n<h2>Reactions &#038; quotes<\/h2>\n<blockquote>\n<p>&#8220;It\u2019s a big multiplier on the eligible pool,&#8221;<\/p>\n<p><cite>Dave Ricks, CEO, Eli Lilly (on Medicare coverage expanding patient access)<\/cite><\/p><\/blockquote>\n<p>Ricks said Medicare coverage will expand the pool of patients eligible for obesity treatments and that volume gains should accelerate later in the year.<\/p>\n<blockquote>\n<p>&#8220;We see sales and profit declining as much as 13% this year,&#8221;<\/p>\n<p><cite>Novo Nordisk (company guidance)<\/cite><\/p><\/blockquote>\n<p>Novo\u2019s guidance, provided earlier in the week, framed a contrasting near\u2011term outlook tied to U.S. price reductions and expiring exclusivities in several international markets.<\/p>\n<aside>\n<details>\n<summary>Explainer: GLP\u20111 drugs and market dynamics<\/summary>\n<p>GLP\u20111 receptor agonists are a class of medicines originally developed for type 2 diabetes that also reduce body weight. Their clinical benefits have driven rapid uptake, sparking intense demand and competition. Pricing, payer coverage and formulation (injectable vs. oral) determine access and revenue; broader public programs and direct\u2011to\u2011consumer discounts can increase treated populations but typically reduce realized prices. Manufacturers pursue volume expansion, lifecycle extensions and international launches to sustain growth.<\/p>\n<\/details>\n<\/aside>\n<h2>Unconfirmed<\/h2>\n<ul>\n<li>The precise launch date and adoption rate for the Trump administration\u2019s direct\u2011to\u2011consumer platform (TrumpRx) remain unclear and could shift the timing of consumer\u2011level price effects.<\/li>\n<li>The exact approval timing and commercial rollout schedule for Lilly\u2019s oral GLP\u20111 obesity pill are pending U.S. regulatory action and could change expected Q2 launch assumptions.<\/li>\n<li>How quickly Medicare implementation details translate into broader prescriptions and payer reimbursements is uncertain and will materially affect volume ramps.<\/li>\n<\/ul>\n<h2>Bottom line<\/h2>\n<p>Lilly\u2019s Q4 beat and bullish 2026 guidance show that in the near term the company expects volume growth and new coverage policies to more than offset price concessions. The firm is leveraging strong demand for Mounjaro and Zepbound and positioning an oral GLP\u20111 to sustain momentum. Investors should monitor realized price trends closely: a low\u2011to\u2011mid\u2011teens global price decline is material and will test the company\u2019s ability to convert higher prescription volumes into lasting profit growth.<\/p>\n<p>For policymakers and payers, the results underscore the trade\u2011offs of broader coverage\u2014greater access and public\u2011health benefits versus lower per\u2011unit revenue for manufacturers. Outcomes over 2026 will depend on how quickly Medicare coverage expands in practice, the timing of new product approvals, and competitive moves from Novo Nordisk and other entrants.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.cnbc.com\/2026\/02\/04\/eli-lilly-lly-earnings-q4-2025.html\" target=\"_blank\" rel=\"noopener\">CNBC<\/a> \u2014 news report on Lilly Q4 results and guidance (media)<\/li>\n<li><a href=\"https:\/\/investor.lilly.com\/\" target=\"_blank\" rel=\"noopener\">Eli Lilly Investor Relations<\/a> \u2014 company presentation and earnings release (official)<\/li>\n<li><a href=\"https:\/\/www.lseg.com\/\" target=\"_blank\" rel=\"noopener\">LSEG<\/a> \u2014 consensus estimates referenced for analyst expectations (market data provider)<\/li>\n<li><a href=\"https:\/\/www.dowjones.com\/products\/street-account\/\" target=\"_blank\" rel=\"noopener\">StreetAccount (Dow Jones)<\/a> \u2014 quarterly product sales comparisons and analyst expectations (market analytics)<\/li>\n<li><a href=\"https:\/\/www.novonordisk.com\/\" target=\"_blank\" rel=\"noopener\">Novo Nordisk<\/a> \u2014 company guidance and commentary (official)<\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Lead: Eli Lilly reported a stronger-than-expected fourth quarter on Feb. 4, 2026, driven by surging demand for its GLP\u20111 drugs Zepbound and Mounjaro. The company posted $19.29 billion in Q4 revenue and a sharply raised 2026 revenue outlook of $80 billion to $83 billion, well above analysts&#8217; $77.62 billion projection. Lilly also set adjusted EPS &#8230; <a title=\"Lilly Crushes Q4 Estimates, Forecasts $80\u201383B as GLP\u20111 Sales Surge\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/lilly-q4-glp1-sales-soar\/\" aria-label=\"Read more about Lilly Crushes Q4 Estimates, Forecasts $80\u201383B as GLP\u20111 Sales Surge\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":17837,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"Lilly Crushes Q4 Estimates, Forecasts $80\u201383B \u2014 Insight Brief","rank_math_description":"Eli Lilly beat Q4 expectations and raised 2026 guidance to $80\u2013$83B as Zepbound and Mounjaro volumes surged, offsetting price declines and boosting market share.","rank_math_focus_keyword":"eli lilly,zepbound,mounjaro,glp-1,earnings,drug pricing","footnotes":""},"categories":[2],"tags":[],"class_list":["post-17843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/17843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=17843"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/17843\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/17837"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=17843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=17843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=17843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}